Cerepro Approved On A Named Patient Basis

Finland's National Agency for Medicines has approved Ark Therapeutics' Cerepro (sitimagene ceradenovec) on a named patient basis. The drug is a novel gene-based therapy, developed as an orphan drug, for the treatment of patients with operable malignant brain tumours and given in addition to surgery and radiotherapy/chemotherapy.

To read the full article, please choose one of the following options: